NeuroSense 1st patient in Phase 2 Alzheimer's disease study expected to be enrolled this moth

 

• Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early December 2023
• Patients who completed the 18-month PARADIGM trial, including the 6-month double-blind study plus the 12-month open label extension, have requested to continue treatment with PrimeC 
• First patient in Phase 2 Alzheimer's disease study expected to be enrolled December 2023
• Cash runway beyond topline clinical study readouts, into Q2 2024

https://www.prnewswire.com/news-releases/neurosense-announces-third-quarter-2023-financial-results-and-provides-business-update-301999234.html